Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 -0.19%60 Buyback Yield % is 0.72 as of Jul. 22, 2026, which is 22% above its 10-year median of 0.59. GuruFocus rates FRA:KN8 with a GF Score™ of 60/100 and a GF Value™ of €148.59 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 291 Drug Manufacturers companies, Krka DD ranks better than 80.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Krka DD's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:KN8 vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Krka DD's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (FRA:KN8) has a Buyback Yield % of 0.72 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Krka DD and its competitors. This is 22% above median its historical median of 0.59. Over the past decade, Krka DD's Buyback Yield % has ranged from 0.33 to 1.15. According to the industry distribution chart, Krka DD ranks #57 out of 291 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Krka DD's Buyback Yield % too high?
Krka DD's current Buyback Yield % of 0.72 is 22% above median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 1.15. Based on the distribution chart, Krka DD ranks #57 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #57 out of 291 companies for Buyback Yield %. This places Krka DD in the top 20% of its industry — outperforming the majority of peers. Historically, Krka DD's own Buyback Yield % has ranged from 0.33 to 1.15 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Krka DD and its competitors. Krka DD's current Buyback Yield % is 0.72, which is 22% above median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Significantly Overvalued. The stock's GF Value™ is €148.59, compared to a current price of €263.00 — trading 77% above its estimated fair value. The current Buyback Yield % is 0.72, which is 22% above median its 10-year median of 0.59. Krka DD's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current Buyback Yield % is 0.72 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €263.00 is trading 77% above its estimated GF Value™ of €148.59.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for FRA:KN8:
Buyback Yield %: 0.72 (22% above median its 10-year median of 0.59)
GF Value™: €148.59 vs. price of €263.00 (77% above fair value)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
60GF Score
Get the complete analysis for FRA:KN8
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
